Pirdal 15 mL nasal spray with its green and white carton, labelled ages 3+.

Medical devices · Private label

PirdalCold

A nasal spray that decongests, cleanses and protects the nasal lining. Pirdal relieves symptoms associated with mild to moderate viral upper respiratory tract infections in adults and children aged 3 years and over. It helps ease nasal congestion and clear excess mucus.

This medical device is available as a 15 mL nasal spray for partners who want to market it under their own brand.

Medical device · Class IIaMDR 2017/745Ages 3 and overNasal spray · 15 ml
Market under your brand

Your nasal spray for cold symptoms,
under your brand

Clinical study

A randomised multicentre study in 213 adults with early COVID-19.

Population

Adults and children aged 3 and over.

Indication

Relief of symptoms associated with mild to moderate viral upper respiratory tract infections.

Benefits
for patients

  • Relieves cough associated with viral upper respiratory tract infections.
  • Relieves nasal congestion.
  • Helps clear excess mucus and secretions.
  • Forms a local protective film on the nasal lining.
  • Immediate action (mechanical osmotic action).
  • Ages 3+.

Mode of action

Pirdal coats the nasal lining with a layer of filmogenic glycerol stabilised by plant-derived polymers.

  • Decongests through osmotic action that draws fluid towards the nasal surface.
  • Cleanses by helping clear excess mucus and material from the nasal surface.
  • Protects by forming a local film over the nasal lining.

The mechanical osmotic action begins on application.

Clinical study · Viral upper respiratory tract infections

Clinical study

Greater improvement in cough-related symptoms by Day 14. A randomised, multicentre study in adults with early COVID-19 compared Pirdal plus standard care (107 participants) with standard care alone (106 participants).

At Day 14, the mean cough-related symptom score fell by 76% from baseline with Pirdal plus standard care and by 33% with standard care alone. The between-group difference at Day 14 was statistically significant (p < 0.001).

Local application-related reactions observed in the study were mild and transient.

The full clinical dossier is available on request under a confidentiality agreement.

Request the dossier under NDA →

Manufacturing & quality

Origine France Garantie label

Certified French manufacturing

Pirdal is manufactured in France at the Vitrobio laboratory. Its Origine France Garantie certification is issued by Bureau Veritas.

ISO 13485
Quality management system certified by GMED.

Product details

FieldValue
CodePIR
Public namePirdal
Product typeMedical device
Regulatory classClass IIa
Regulatory frameworkRegulation (EU) 2017/745 on medical devices
Notified BodyGMED
Population / ageAdults and children aged 3 years and over
CategoryCold
Full official indicationRelief of symptoms associated with mild to moderate viral upper respiratory tract infections
CompositionFilmogenic glycerol, S1-cyanidins
Format / volume15 mL nasal spray
Legal manufacturerVitrobio SAS
Country of manufactureFrance, in-house manufacturing
Quality systemQuality management system certified to ISO 13485 by GMED

Let's discuss
this product

To market this product under your brand, tell us about your company and target countries.

← Back to medical devices